Precision Nanomedicine

AIBN researchers have developed a new way to produce nanoparticles that carry much higher drug concentrations.

AIBN researchers have discovered that hard nanoparticles can enter human cells, including cancer cells, much more easily than soft ‘squishy’ nanoparticles. The findings will help to guide the design of more potent, highly targeted treatments for a range of diseases.

Nanotechnology developed to detect cancer can also identify signals released by cancer cells, possibly resulting in earlier diagnosis and better treatment.

Dr Hang Ta has received funding from the Heart Foundation for her research into how nanomedicines could detect and treat heart disease.

An Australian gold mining company will aid the development of a rapid cancer test with a $300,000 donation to AIBN.

Researchers from the University of Queensland’s Australian Institute for Bioengineering and Nanotechnology (AIBN) have discovered a unique nano-scaled DNA signature that appears to be common to all cancers.

Research led by Professor Gordon Xu of the Australian Institute for Bioengineering and Nanotechnology (AIBN) has shown that clay nanoparticles can significantly boost immune responses as vaccine adjuvants.

UQ Researchers have developed a new nanotechnology to monitor drug resistance and diversity of individual cancer cells circulating in the body.

Researchers have developed a new approach to delivering DNA into cells using spikey silica nanoparticles. These nanoparticles transport the genetic cargo across the cell wall while protecting it from degradation.

Trau group researchers are using nanotechnology for fabrication-free disease biomarker detection within a fluidic droplet. The “lab-in-a-drop” system can be extremely useful for the detection of disease nucleic acid biomarkers.